1. Home
  2. RGS vs MDXH Comparison

RGS vs MDXH Comparison

Compare RGS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regis Corporation

RGS

Regis Corporation

SELL

Current Price

$29.00

Market Cap

72.6M

ML Signal

SELL

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.20

Market Cap

68.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGS
MDXH
Founded
1922
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
72.6M
68.7M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
RGS
MDXH
Price
$29.00
$0.20
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.80
AVG Volume (30 Days)
4.7K
★ 220.4K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 2.41
N/A
Revenue
★ $224,485,000.00
N/A
Revenue This Year
N/A
$5.10
Revenue Next Year
$1.68
$13.22
P/E Ratio
$12.11
★ N/A
Revenue Growth
★ 6.83
N/A
52 Week Low
$19.31
$0.40
52 Week High
$30.93
$5.33

Technical Indicators

Market Signals
Indicator
RGS
MDXH
Relative Strength Index (RSI) 52.89 20.10
Support Level $26.23 N/A
Resistance Level $29.65 $0.64
Average True Range (ATR) 0.59 0.06
MACD -0.05 -0.02
Stochastic Oscillator 52.94 0.47

Price Performance

Historical Comparison
RGS
MDXH

About RGS Regis Corporation

Regis Corporation franchises, owns, and operates hair care salons, mainly in North America, with licensed locations in the U.K. Its salons provide haircutting, styling, shampooing and conditioning, hair coloring and related services, and also sell hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, Cost Cutters, First Choice Haircutters and Roosters. Its operating segments are Franchise and Company-Owned, with the majority of its revenue generated from the Franchise segment.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: